Market Cap $80 M--Cash $22 Million --FDA Decision on November 30 -- 3 Marketed Drugs including former Blockbuster Suboxone film (opioid dependence) -- 4 Drugs under review by FDA 3 of them with MASSIVE market potential /Undiscovered Low float gem = Potential 10 Bagger here guys ..Check it out this one could run massive ahead of the PDUFA date next month .GL Aquestive Therapeutics (AQST) Market Cap $80 Million Cash: $22 Million Price: $3.20 Presentation http://investors.aquestive.com/static-files/01374d64-cc08-4bc1-89e8-b6008edb43a6 Insider buying http://openinsider.com/search?q=aqst
market cap of $83 miillion is a GIFT should be north of $500 million .. Upcoming MAJOR Milestones expected during Q4 2019 : FDA Decision für Exservan (amyotrophic lateral sclerosis) on November 30 PoC results (Acromegalie Oral film) during this Q NDA submission for Libervant this Q NDA resubmission Parkinson drug this Q Lagrest Shareholder Crestline ...11.5M Perceptive ...2.1M Monosol ...1.9M Schobel ...1.1M Kendall (Keith J.) ...729.2K Opaleye ...590.0K MFS Investment ...473.3K BlackRock ...378.3K Bratton (Douglas K) ...335.0K The Vanguard ...312.1K
good numbers ... Aquestive backs FY19 revenue $38M-$45M, consensus $42.82M Aquestive Therapeutics announced, in response to Indivior PLC's press release issued earlier today of Indivior's intent to cease production of its authorized generic buprenorphine-naloxone film product, that the company is reaffirming its full year 2019 total revenue guidance. Full year 2019 total revenue is now expected to be at the top end of the company's guidance range of $38M-$45M. Full year 2019 revenue from the company's Suboxone franchise is expected to be at the top end of its guidance range of $29M-$32M. As of October 2019, Suboxone and the authorized generic buprenorphine-naloxone film continue to retain approximately 75% of the market for film treatments of opioid dependence, of which a substantial majority of its retained market share is branded Suboxone. Read more at: https://thefly.com/landingPageNews.php?id=2975849
They presently have a $34.00 price objective on the stock. https://nctynews.com/wedbush-reaffirms-buy-rating-for-aquestive-therapeutics-nasdaqaqst/
I got in at 6.43,...big buzz going on in the chat forums about the potential of this stock....we shall see.